Supera self-expanding stents for endovascular treatment of femoropopliteal disease

A review of the clinical evidence

Kalkidan Bishu, Ehrin J. Armstrong

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel–titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel–titanium alloy stent system with other stent platforms and angioplasty alone are needed.

Original languageEnglish (US)
Pages (from-to)387-395
Number of pages9
JournalVascular Health and Risk Management
Volume11
DOIs
StatePublished - Jul 13 2015
Externally publishedYes

Fingerprint

Stents
Arteries
Therapeutics
Peripheral Arterial Disease
Hip Joint
Knee Joint
Thigh
Angioplasty
Ischemia
Extremities
Joints

Keywords

  • Femoropopliteal atherosclerosis
  • Peripheral artery disease
  • Stent fracture
  • SUPERA interwoven nitinol stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Supera self-expanding stents for endovascular treatment of femoropopliteal disease : A review of the clinical evidence. / Bishu, Kalkidan; Armstrong, Ehrin J.

In: Vascular Health and Risk Management, Vol. 11, 13.07.2015, p. 387-395.

Research output: Contribution to journalArticle

@article{bdd93dac27e4407c85a21d486c6a9370,
title = "Supera self-expanding stents for endovascular treatment of femoropopliteal disease: A review of the clinical evidence",
abstract = "Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel–titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel–titanium alloy stent system with other stent platforms and angioplasty alone are needed.",
keywords = "Femoropopliteal atherosclerosis, Peripheral artery disease, Stent fracture, SUPERA interwoven nitinol stent",
author = "Kalkidan Bishu and Armstrong, {Ehrin J.}",
year = "2015",
month = "7",
day = "13",
doi = "10.2147/VHRM.S70229",
language = "English (US)",
volume = "11",
pages = "387--395",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Supera self-expanding stents for endovascular treatment of femoropopliteal disease

T2 - A review of the clinical evidence

AU - Bishu, Kalkidan

AU - Armstrong, Ehrin J.

PY - 2015/7/13

Y1 - 2015/7/13

N2 - Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel–titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel–titanium alloy stent system with other stent platforms and angioplasty alone are needed.

AB - Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel–titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel–titanium alloy stent system with other stent platforms and angioplasty alone are needed.

KW - Femoropopliteal atherosclerosis

KW - Peripheral artery disease

KW - Stent fracture

KW - SUPERA interwoven nitinol stent

UR - http://www.scopus.com/inward/record.url?scp=84939812942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939812942&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S70229

DO - 10.2147/VHRM.S70229

M3 - Article

VL - 11

SP - 387

EP - 395

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -